Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

Biden co-hosting 2nd COVID summit as world's resolve falters

President Joe Biden will appeal for a renewed international commitment to attacking COVID-19 as the second global COVID-19 summit opens

The Independent UK

How Russia's war has hit Thailand, 11 weeks on

In recent months there have been positive signs that the world is returning to normal after the Covid-19 pandemic. People have worked tirelessly over the past two years to address and mitigate the consequences of the pandemic, spending billions on healthcare, vaccine development and deployment, social assistance payments, and other…

Bangkok Post

400 million COVID-19 vaccine doses dumped by Baltimore plant, congressional report finds

BALTIMORE — The Maryland-based vaccine maker Emergent BioSolutions was forced to destroy nearly 400 million doses of COVID-19 vaccine because of potential contamination at its East Baltimore plant, far more than previously known.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Sir John Bell: ‘Most people who have had the Covid vaccine are completely safe’

The renowned immunologist remains as upbeat about jabs – and UK life science – as he was in the depths of the pandemic

The Guardian - UK

The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

FDA Accepts AstraZeneca's sBLA for Imfinzi (durvalumab) in biliary tract cancer (BTC) with Priority Review

The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca's (NASDAQ: AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy and granted Priority Review for patients with locally advanced or metastatic biliary tract cancer (BTC).

Benzinga

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Families of people who died after taking Covid vaccine ‘ignored’ as zero compensation payouts made

More than 1,200 claims have been made to the government’s Vaccines Damages Payment Scheme, but no compensation has yet to be paid out

The Independent UK

48 Stocks Moving In Friday's Mid-Day Session

Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS.

Benzinga

AstraZeneca boss calls for UK to provide new Covid-19 medicine to the vulnerable

Pharmaceutical CEO says it’s ‘sad’ that UK has failed to order Evusheld for the immunosuppressed

The Guardian - UK

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

AstraZeneca: Q1 Earnings Insights

AstraZeneca (NASDAQ:AZN) reported its Q1 earnings results on Friday, April 29, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings AstraZeneca reported an EPS of $1.89.

Benzinga

AstraZeneca faces revenue hit as Covid-19 vaccine demand falls

Pharmaceutical giant has also announced plans to open a new research and development centre in Boston, Massachusetts

Evening Standard

AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

AstraZeneca Plc's (NASDAQ:AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicines and several Vaxzevria contracts that are expected to complete the delivery by half year 2022. Core EPS came in at $1.89,…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Sales of Covid vaccine set to decline as demand wanes, AstraZeneca predicts

The business has already seen a significant drop in the use of its vaccines to Europe.

Benzinga

How To Attend AstraZeneca Q1 2022 Earnings Conference Call

AstraZeneca (NASDAQ:AZN) will host a conference call at 06:45 AM ET on April 29, 2022, to discuss Q1 2022 earnings results. How to Attend AstraZeneca (AZN) Conference Call Follow this link to access the live webcast.

Manchester Evening News

Latest data shows significant rise in Covid deaths in England and Wales for third week in a row

Deaths involving Covid-19 are up 13 per cent on last week, the latest data shows

Benzinga

If You Invested $100 In AstraZeneca 5 Years Ago, Here's How Much You Would Have Today

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.24% on an annualized basis producing an average annual return of 17.72%. Currently, AstraZeneca has a market capitalization of $213.61 billion.

Get all your
news in one place.

100’s of premium titles.
One news app.

Wales Online

Covid booster gives long-lasting protection, study finds

'The longer-term protection against hospitalisation and death is perhaps the most important factor for future booster programmes'

The Independent UK

Third Covid-19 vaccine dose offers ‘prolonged immune response’ – UK-wide study

The study compared immune responses to seven vaccines used as a booster 28 days after two initial doses.

Benzinga

AstraZeneca's COVID-19 Antibody Provides Protection For At Least Six Months In High-Risk Individuals

AstraZeneca plc (NASDAQ:AZN) shared detailed results from the PROVENT Phase 3 pre-exposure prophylaxis (prevention) trial of Evusheld (tixagevimab and cilgavimab), formerly AZD7442. The data showed that Evusheld reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and 83% in the six-month follow-up analysis, compared to placebo. There were no…

Evening Standard

Covid-19 vaccine maker Oxford Biomedica pauses production as AstraZeneca partnership reviewed

Shares in the FTSE 250 company slumped as much as 10% as it warned revenues will be lower this year than last

The Conversation

The Valneva COVID vaccine has been approved for use in the UK – here's what the evidence says

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new COVID vaccine. VLA2001 is manufactured by French pharmaceutical company Valneva for use in the UK and was approved on April 14 for use in adults between the ages of 18 and 50 for first and second doses.

Daily Record

Covid vaccine developed in West Lothian is approved

It is the sixth Covid-19 vaccine to be granted an MHRA authorisation for use in Britain

Evening Standard

GlaxoSmithKline and AstraZeneca secure victories with US drug regulator

GlaxoSmithKline’s drug aimed at chronic kidney disease patients with anaemia and AstraZeneca’s lung cancer treatment have both moved a step closer to getting the green light

1 … 18 19 20 21

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.